ABAX - Nasdaq, Abaxis Announces Licensing of Lyophilization Technology to bioMerieux
UNION CITY, Calif., March 21 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(Nasdaq: ABAX), a medical products company manufacturing point-of-care blood
analysis systems, announced today that it has completed an agreement to
license a portion of its patent portfolio covering lyophilization technology
to bioMerieux SA.
"Our Orbos lyophilization technology, through the freeze drying of
reagents in small quantities, enables efficient manufacturing of reagents in a
convenient and stable format. This license with bioMerieux once again shows
that our Orbos technology is quickly becoming a standard format for reagent
utilization in molecular diagnostics," said Kenneth Aron, Ph.D.,
Vice-President of R&D at Abaxis.
"We now have several major companies utilizing our Orbos lyophilization
technology. All of these companies have recognized the utility of our
freeze-drying solution and are committed to utilizing our technology in a
number of their product lines."
Dr. Aron continued, "We see significant opportunities for further
licensing in the fields of molecular diagnostics and environmental monitoring.
These licensing opportunities are particularly attractive to Abaxis since
these fields are complementary to our own but in no way compete with our core
business of clinical chemistry. Since we get additional recurring revenue for
Abaxis, these licenses all represent classic win-win scenarios for us and for
our present and future licensees."
Abaxis does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
Contact: Clint Severson Lytham Partners, LLC
Chief Executive Officer Joe Dorame, Robert Blum, Joe Diaz
Abaxis, Inc. 602-889-9700
510-675-6500
SOURCE Abaxis, Inc.
Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or
Joe Dorame, or Robert Blum, or Joe Diaz, all of Lytham Partners, LLC,
+1-602-889-9700, for Abaxis, Inc.
21Mar06 11:30 GMT
Symbols:
us;ABAX
Source PRN PR Newswire
Categories:
